Bevacizumab-induced hypertension is a predictive marker for improved outcomes in patients with recurrent glioblastoma treated with bevacizumab.
Phase of Trial: Phase II
Latest Information Update: 28 Dec 2015
At a glance
- Drugs Bevacizumab (Primary)
- Indications Glioblastoma
- Focus Adverse reactions; Biomarker; Therapeutic Use
- 28 Dec 2015 New trial record